Literature DB >> 1606527

The immunoregulatory effects of IVIG in Kawasaki disease and other autoimmune diseases.

D Y Leung1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1606527     DOI： 10.1007/978-1-4612-0417-6_8

Source DB:  PubMed          Journal:  Clin Rev Allergy        ISSN： 0731-8235


× No keyword cloud information.
  38 in total

1.  Centers for Disease Control (CDC) case definition for Kawasaki syndrome.

Authors:  A M Rauch; E S Hurwitz
Journal:  Pediatr Infect Dis       Date:  1985 Nov-Dec

2.  Serum-soluble interleukin-2 receptor levels in Kawasaki disease.

Authors:  B A Lang; E D Silverman; R M Laxer; V Rose; D L Nelson; L A Rubin
Journal:  J Pediatr       Date:  1990-04       Impact factor: 4.406

3.  Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

Authors:  Y Sultan; M D Kazatchkine; P Maisonneuve; U E Nydegger
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

4.  Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.

Authors:  J Fehr; V Hofmann; U Kappeler
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

Review 5.  Pathogenic mechanisms in autoimmune diseases.

Authors:  N R Rose
Journal:  Clin Immunol Immunopathol       Date:  1989-11

6.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors:  T Kawasaki
Journal:  Arerugi       Date:  1967-03

7.  Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases.

Authors:  A Suzuki; T Kamiya; N Kuwahara; Y Ono; T Kohata; O Takahashi; K Kimura; M Takamiya
Journal:  Pediatr Cardiol       Date:  1986       Impact factor: 1.655

8.  Class II major histocompatibility antigen expression on coronary arterial endothelium in a patient with Kawasaki disease.

Authors:  M Terai; Y Kohno; M Namba; T Umemiya; K Niwa; H Nakajima; A Mikata
Journal:  Hum Pathol       Date:  1990-02       Impact factor: 3.466

9.  Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin.

Authors:  D Y Leung; J C Burns; J W Newburger; R S Geha
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

10.  High-dose intravenous gammaglobulin for Kawasaki disease.

Authors:  K Furusho; T Kamiya; H Nakano; N Kiyosawa; K Shinomiya; T Hayashidera; T Tamura; O Hirose; Y Manabe; T Yokoyama
Journal:  Lancet       Date:  1984-11-10       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.